[go: up one dir, main page]

AR082340A1 - Metodos y composiciones para la terapia del cancer de higado - Google Patents

Metodos y composiciones para la terapia del cancer de higado

Info

Publication number
AR082340A1
AR082340A1 ARP110102679A ARP110102679A AR082340A1 AR 082340 A1 AR082340 A1 AR 082340A1 AR P110102679 A ARP110102679 A AR P110102679A AR P110102679 A ARP110102679 A AR P110102679A AR 082340 A1 AR082340 A1 AR 082340A1
Authority
AR
Argentina
Prior art keywords
liver cancer
methods
compositions
cancer therapy
progastrin
Prior art date
Application number
ARP110102679A
Other languages
English (en)
Inventor
Leila Houhou
Anne Dume
Dominique Sophie-Joubert
Frederic Hollande
Original Assignee
Biorealites S A S
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorealites S A S, Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Biorealites S A S
Publication of AR082340A1 publication Critical patent/AR082340A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Métodos para tratar el cáncer de hígado y prevenir la recurrencia del cáncer de hígado, con anticuerpos anti-progastrina, métodos para llevar un control de la eficacia del tratamiento de la terapia con anti-progastrina para el cáncer de hígado y composiciones de utilidad para ello.
ARP110102679A 2010-07-26 2011-07-25 Metodos y composiciones para la terapia del cancer de higado AR082340A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36785110P 2010-07-26 2010-07-26
US201161476204P 2011-04-15 2011-04-15

Publications (1)

Publication Number Publication Date
AR082340A1 true AR082340A1 (es) 2012-11-28

Family

ID=45493809

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102679A AR082340A1 (es) 2010-07-26 2011-07-25 Metodos y composiciones para la terapia del cancer de higado

Country Status (16)

Country Link
US (1) US10533050B2 (es)
EP (1) EP2598531B1 (es)
JP (1) JP5726305B2 (es)
KR (1) KR101576174B1 (es)
CN (1) CN103261224B (es)
AR (1) AR082340A1 (es)
AU (1) AU2011284908B2 (es)
BR (1) BR112013002012A2 (es)
CA (1) CA2806157C (es)
EA (2) EA201790882A1 (es)
ES (1) ES2871092T3 (es)
NZ (1) NZ606195A (es)
PL (1) PL2598531T3 (es)
SG (2) SG10201703556YA (es)
WO (1) WO2012013609A1 (es)
ZA (1) ZA201300567B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010016527A1 (ja) 2008-08-05 2010-02-11 東レ株式会社 癌の検出方法
CN102170907A (zh) 2008-08-05 2011-08-31 东丽株式会社 用于治疗和预防癌症的药物组合物
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
KR101805520B1 (ko) 2010-02-04 2017-12-07 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
MX349907B (es) 2011-08-04 2017-08-18 Toray Industries Metodo para detectar cancer pancreatico.
RU2630638C2 (ru) 2011-08-04 2017-09-11 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы
HUE047006T2 (hu) 2011-08-04 2020-04-28 Toray Industries Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
PT2818483T (pt) 2012-02-21 2017-10-09 Toray Industries Composição medicinal para tratamento e/ou prevenção de cancro
KR102005308B1 (ko) 2012-02-21 2019-07-30 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
IN2014KN01713A (es) 2012-02-21 2015-10-23 Toray Industries
ES2739380T3 (es) 2012-02-21 2020-01-30 Toray Industries Composición farmacéutica para el tratamiento del cáncer
CA2869120C (en) * 2012-03-30 2023-05-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
CN104203281B (zh) 2012-03-30 2019-07-26 东丽株式会社 胆囊癌的治疗和/或预防用药物组合物
DK2876447T3 (da) 2012-07-19 2020-02-24 Toray Industries Fremgangsmåde til detektering af cancer
DK2876446T3 (en) 2012-07-19 2019-03-11 Toray Industries Method for detecting cancer
RU2678138C2 (ru) 2013-08-09 2019-01-23 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
CN107073129B (zh) * 2014-09-10 2021-10-15 双键医药品股份公司 亲水性药物的靶向递送
EP3023884A1 (en) * 2014-11-21 2016-05-25 Thomson Licensing Method and apparatus for generating fingerprint of an audio signal
KR102428254B1 (ko) 2015-12-31 2022-08-03 프로가스트린 에 캔서스 에스.에이 알.엘. 난소암의 검출 및 치료를 위한 조성물 및 방법
EP3397967B1 (en) 2015-12-31 2020-12-30 Progastrine et Cancers S.à r.l. Compositions and methods for detecting and treating esophageal cancer
EP3397966B1 (en) 2015-12-31 2021-09-29 Progastrine et Cancers S.à r.l. Compositions and methods for detecting and treating gastric cancer
SG11201804629XA (en) 2015-12-31 2018-07-30 Syncerus S A R L Compositions and methods for assessing the risk of cancer occurrence
CA3058265C (en) 2017-03-30 2023-03-14 Progastrine Et Cancers S.A R.L. Compositions and methods for treating lung cancer
SG11201908998XA (en) 2017-03-30 2019-10-30 Progastrine Et Cancers S A R L Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
CA3084687C (en) * 2017-12-05 2024-01-02 Progastrine Et Cancers S.A R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
EP3720510A1 (en) 2017-12-08 2020-10-14 Ecs-biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
WO2019145537A1 (en) 2018-01-26 2019-08-01 Ecs-Progastrin Sa Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
JP7485274B2 (ja) * 2018-02-27 2024-05-16 イー、シー、エス、プロガストリン、エス、エー 免疫療法のためのバイオマーカーとしてのプロガストリン
US20210101974A1 (en) * 2019-10-02 2021-04-08 Alamab Therapeutics, Inc. Anti-connexin antibody formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2286883T3 (es) * 1998-05-15 2007-12-01 Receptor Biologix, Inc. Prevencion y tratamiento de la hipergastrinemia.
US20030021786A1 (en) * 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
EP1631236A2 (en) * 2003-06-02 2006-03-08 Alexion Pharmaceuticals, Inc. Cell surface protein associated with human chronic lymphocytic leukemia
DK1794586T3 (da) * 2004-09-22 2013-05-13 Cancer Advances Inc Monoklonale antistoffer til progastrin
CA2652768A1 (en) * 2006-05-22 2007-11-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibitors of progastrin-induced repression of icat for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells andcells in which the beta-catenin/tcf-4-mediated transcriptional pathway is constitutively active
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
AU2010306119A1 (en) * 2009-10-16 2012-05-03 Centre National De La Recherche Scientifique (Cnrs) Monoclonal antibodies to progastrin and their uses
US9217032B2 (en) * 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
EP2550294B1 (en) * 2010-03-24 2019-08-21 Progastrine et Cancers S.à r.l. Prophylaxis of colorectal and gastrointestinal cancer

Also Published As

Publication number Publication date
CN103261224B (zh) 2015-10-07
EA028515B1 (ru) 2017-11-30
EP2598531A1 (en) 2013-06-05
KR101576174B1 (ko) 2015-12-09
JP5726305B2 (ja) 2015-05-27
AU2011284908B2 (en) 2015-05-21
EA201300171A1 (ru) 2013-07-30
EP2598531B1 (en) 2020-12-30
EA201790882A1 (ru) 2017-08-31
WO2012013609A1 (en) 2012-02-02
CN103261224A (zh) 2013-08-21
ES2871092T3 (es) 2021-10-28
NZ606195A (en) 2015-02-27
CA2806157C (en) 2016-11-22
SG10201703556YA (en) 2017-06-29
KR20130083438A (ko) 2013-07-22
JP2013533277A (ja) 2013-08-22
SG187544A1 (en) 2013-03-28
ZA201300567B (en) 2014-03-26
PL2598531T3 (pl) 2021-08-30
CA2806157A1 (en) 2012-02-02
BR112013002012A2 (pt) 2019-08-27
US20120020961A1 (en) 2012-01-26
AU2011284908A1 (en) 2013-02-07
US10533050B2 (en) 2020-01-14

Similar Documents

Publication Publication Date Title
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
CL2015002194A1 (es) Inhbidores de erk y sus usos
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
EA201590987A1 (ru) Соединения и способы их применения
CR20120202A (es) Métodos y composiciones para tratar cáncer
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201590997A1 (ru) Соединения и способы их применения
MX360774B (es) Antagonistas de progesterona.
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX2018005348A (es) Composiciones y metodos para transduccion de tumores.
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
EA201890598A3 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.

Legal Events

Date Code Title Description
FB Suspension of granting procedure